Contact: Dennis J. CurtinSenior Vice President - Chief Financial Officer
Telephone: (516) 333-8230, Ext. 3201
Email: dcurtin@ezem.com

E-Z-EM, INC., ANNOUNCES RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2002

Westbury, New York, August 6, 2002 - E-Z-EM, Inc., (AMEX - EZM.A and EZM.B) today announced 
results for the fourth quarter and fiscal year ended June 1, 2002.

For the quarter, the Company reported net earnings of $707,000, $.07 per share on a basic and 
diluted basis, on net sales of $33,217,000. In the fourth quarter of fiscal 2001, E-Z-EM had 
net earnings of $477,000, $.05 per share on a basic and diluted basis, on net sales of 
$31,086,000. The sales growth in the quarter of $2,131,000, or 7%, can be attributed to 
AngioDynamics products and the continued growth in contrast agents for CT procedures. Last 
year’s results were affected by a $566,000 impairment charge relating to the Company’s 
investment in Cedara Software Corporation, and $349,000 in costs associated with the 
relocation of the Company’s operations in the United Kingdom.

For fiscal 2002, the Company posted net earnings of $585,000, $.06 per share on both a basic 
and diluted basis. This compares to fiscal 2001 net earnings of $3,286,000, $.33 and $.32 
per share on a basic and diluted basis, respectively. Net sales increased by 8% to 
$122,133,000 in fiscal 2002 associated with increased AngioDynamics sales, with the 
Company’s Diagnostic segment showing strong growth in contract manufacturing, contrast 
systems and CT injector sales. 

Both fiscal 2002 and 2001 results contained charges for restructuring and the repositioning 
of the Company into new product segments. This year’s results reflect restructuring costs of 
$1,393,000 related to closure of the Company’s Japanese manufacturing facility in December 2001, 
which impacted earnings for the year by $.14 per basic share. Our strategy is to service the 
large Japanese market with contrast systems manufactured in the U.S. In fiscal 2001 several 
factors combined to have an adverse effect on net earnings of $743,000, or $.08 per basic 
share. These factors included the favorable reversal of a tax valuation allowance of 
$1,344,000, offset by several (pre-tax) charges: a reorganization of operations that resulted 
in severance and facility relocation expenses of $886,000; a loss of $872,000 from the sale 
of a manufacturing facility in the Republic of Ireland; the aforementioned Cedara impairment 
charge of $566,000; and the write-down of $450,000 for acquired patent rights to an oral MRI 
contrast agent.

Commenting on the Company’s results for the year, Anthony A. Lombardo, E-Z-EM’s President and 
Chief Executive Officer, said, "During fiscal 2002, our AngioDynamics subsidiary continued 
its strong sales growth, ending the year with an increase of $7.5 million, or 32% ahead of 
last year, driven mainly by our vascular access products. We also experienced growth in our 
angiographic catheters and stent/angioplasty products. Operating profit in this segment 
improved by almost $2.7 million from a year ago and gross profit margins improved by 3 
percentage points. These results validate our decision to focus on the interventional 
radiology area and our continued investment in sales force support and new product line 
extensions. We will soon break ground on an expansion project that will more than double the 
current size of AngioDynamics’ headquarters and manufacturing facility in Queensbury, 
New York. The additional 32,000 square feet will add manufacturing capacity and consolidate 
warehouse and distribution functions. In addition, the Company plans renovations to upgrade 
its research, development and engineering capabilities.

"Sales in our Diagnostic segment increased over last year by $1.7 million due to contributions 
from our contract manufacturing products and continued growth in CT contrast products. The 
operating loss for the year was $.4 million, a decline of $4.3 million from the prior year, 
due to the $1.4 million charge from the Japanese closure expense and continued investment in 
the areas of virtual colonoscopy and CT injector systems. The Diagnostic segment continues to 
lead in the development of clinical systems for supporting the emerging markets in virtual 
colonoscopy. In the later half of fiscal 2002, we received FDA clearance for our PROTOCO2L(TM)
carbon dioxide insufflator, and released the InnerviewGI(TM) 3D software diagnostic platform 
in conjunction with our strategic partner, Vital Images, Inc.

The Company’s cash and short-term marketable securities at June 1, 2002, were $24 million, 
up $6 million from fiscal year end 2001. Net book value per common share outstanding was 
$8.36 at fiscal year end. The Company’s balance sheet and financial position remain strong.

Commenting on the Company’s strategic direction, Mr. Lombardo said, "The Company continues to 
invest in positioning itself in the high growth area of CT systems, including virtual 
colonoscopy, contrast agents and injector systems. Our focus on interventional radiology as 
a best practice company is demonstrating what a concerted investment strategy can produce in 
terms of positioning AngioDynamics as a leading supplier, clinical partner and innovator in 
this rapidly growing marketplace."

About E-Z-EM, Inc. 

E-Z-EM, the world’s largest manufacturer of contrast agents for gastrointestinal radiology, 
has developed the only CT injector on the market that can help detect contrast extravasation, 
the new EmpowerCT(TM) with patented EDA(TM) technology. The Company has also recently 
introduced a complete tool kit for virtual colonoscopy (also referred to as CT colonography, 
or CTC), an innovative technology that could lead to a substantial increase in the number of 
patients being screened for colorectal cancer. Virtual colonoscopy visualizes the 
gastrointestinal tract using advanced CT imaging and 3D computer reconstruction of that 
data. The Company’s product line consists of the InnerviewGI(TM) 3D imaging workstation; 
LoSo Prep(TM) and NutraPrep(TM) patient-friendly colon preparation products and nutritional 
meal kits; a tagging agent trade-named Tagitol(TM) to help practitioners distinguish 
pathology from colonic residue; and the PROTOCO2L(TM) carbon dioxide colon insufflation 
system. 

E-Z-EM’s wholly owned subsidiary, AngioDynamics, manufactures a wide range of products, 
including angiographic, vascular access, thrombolytic, angioplasty, stents, as well as 
abdominal infection drainage products. AngioDynamics’ focus is on diagnostic and therapeutic 
products for interventional radiology and other areas of minimally invasive surgery. Enteric 
Products, Inc., another subsidiary, develops, manufactures and markets tests for detection of 
the ulcer- and cancer-causing bacterium Helicobacter pylori. For additional information, 
please contact Frank Kerrigon at 1-800-544-4624, ext. 325, (E-mail: fkerrigon@ezem.com) or 
visit our corporate web site at www.ezem.com. 

The statements made in this document contain certain forward-looking statements that involve 
a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", 
"plans", "believes", "seeks", "estimates", or variations of such words and similar expressions, 
are intended to identify such forward-looking statements. Investors are cautioned that actual 
events or results may differ from the Company’s expectations. In addition to the matters 
described above, the ability of the Company to develop its products, future actions by the 
FDA or other regulatory agencies, results of pending or future clinical trials, overall 
economic conditions, general market conditions, foreign currency exchange rate fluctuations, 
the effects on pricing from Group Purchasing Organizations, competition, including alternative 
procedures which continue to replace traditional fluoroscopic procedures, as well as the risk 
factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not 
limited to its Annual Report on Form 10-K for the year ended June 1, 2002 may affect the 
actual results achieved by the Company. 
  
End